5月5日，万春医药将披露2024财年年报（数据来源于纳斯达克官网，预计披露日期为美国当地时间，实 际披露日期以公司公告为准）。 财务数据显示，截至2024年06月30日，万春医药收入总额100.0万美元，同比增长14.29%；归母净利 润-726.2万美元，同比增长42.91%。 大事提醒： 8月25日，万春医药(BYSI)开盘上涨6.25%，截至21:31，报1.87美元/股，成交192.0美元，总市值7542.14 万美元。 资料显示，万春药业公司是一家处于全球临床阶段的生物制药公司,专注于新型癌症疗法,包括晚期肿瘤 免疫药物的研发。在BeyondSpring,他们的使命是利用他们癌症治疗的学术及业务能力,采用独有方式来 改变癌症治疗的现状。公司成立于2013年,总部设立在美国。他们的主要项目普那布林来源于天然化合 物,由于所具有的各种生化活性,对多种癌症有治疗潜力。他们采用一种新颖的、高度可扩展的商业模式, 整合美中优势资源,高效、低成本地实现药物的报批和开发。目标研究领域包括:非小细胞肺癌、中性粒 细胞减少症的预防和普那布林+PD-1单抗。 本文源自：金融界 作者：行情君 ...

Core Insights - BeyondSpring Pharmaceuticals (BYSI) experienced a stock price increase of 2.9%, reaching $1.77 per share, with a total market capitalization of $71.38 million as of August 22 [1] - For the fiscal year ending June 30, 2024, the company reported total revenue of $1.00 million, reflecting a year-over-year growth of 14.29%, while the net profit attributable to shareholders was -$7.26 million, showing a year-over-year increase of 42.91% [1] Company Overview - BeyondSpring Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, including advanced tumor immunotherapy [2] - The company was founded in 2013 and is headquartered in the United States, with a mission to transform cancer treatment through its academic and business capabilities [2] - The primary project, Plinabulin, is derived from natural compounds and has therapeutic potential for various cancers, with a unique and scalable business model that integrates resources from the U.S. and China for efficient and low-cost drug approval and development [2] - Target research areas include non-small cell lung cancer, prevention of neutropenia, and Plinabulin combined with PD-1 monoclonal antibodies [2]

Core Insights - BeyondSpring Pharmaceuticals (BYSI) experienced a stock price increase of 5.19%, reaching $1.841 per share with a total market capitalization of $74.24 million as of August 20 [1] - For the fiscal year ending June 30, 2024, the company reported total revenue of $1 million, reflecting a year-over-year growth of 14.29%, while the net profit attributable to shareholders was -$7.262 million, showing a 42.91% increase in losses compared to the previous year [1] Company Overview - BeyondSpring is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, including advanced tumor immunotherapy [1] - The company was founded in 2013 and is headquartered in the United States, aiming to transform cancer treatment through its academic and business capabilities [1] - The primary project, Plinabulin, is derived from natural compounds and has therapeutic potential for various cancers due to its biochemical activities [1] Business Model and Research Focus - BeyondSpring employs a novel, highly scalable business model that integrates resources from both the U.S. and China to efficiently and cost-effectively achieve drug approval and development [1] - The target research areas include non-small cell lung cancer, prevention of neutropenia, and the combination of Plinabulin with PD-1 monoclonal antibodies [1]

[Forward-Looking Statements](index=4&type=section&id=FORWARD-LOOKING%20STATEMENTS) [Forward-Looking Statements](index=4&type=section&id=FORWARD-LOOKING%20STATEMENTS) This section cautions investors that forward-looking statements involve risks and uncertainties, and actual results may differ - The report identifies numerous forward-looking statements concerning the company's operations, including clinical trial progress, regulatory filings, commercialization potential, financial projections, and intellectual property strategy[12](index=12&type=chunk)[16](index=16&type=chunk) - Investors are directed to "Part II, Item 1A. Risk Factors" for a detailed discussion of risks that could cause actual results to differ from those projected in the forward-looking statements[11](index=11&type=chunk)[13](index=13&type=chunk) [PART I. FINANCIAL INFORMATION](index=6&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Financial Statements](index=6&type=section&id=Item%201.%20Financial%20Statements) Unaudited Q2 2025 financial statements report a net loss of $4.6 million, reclassifying SEED Therapeutics as a discontinued operation [Condensed Consolidated Balance Sheets](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2025, total assets decreased to **$31.0 million**, while cash from continuing operations increased to **$9.5 million** Condensed Consolidated Balance Sheet Highlights (in thousands of U.S. Dollars) | Account | Dec 31, 2024 | June 30, 2025 (Unaudited) | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $2,922 | $9,544 | | Current assets of discontinued operations | $25,347 | $15,712 | | Total assets | $34,315 | $31,043 | | **Liabilities & Equity** | | | | Total current liabilities | $11,010 | $11,730 | | Total liabilities | $48,600 | $48,588 | | Total shareholders' deficit | ($14,285) | ($17,545) | [Condensed Consolidated Statements of Comprehensive Income (Loss)](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Comprehensive%20Income%20(Loss)) For H1 2025, net loss from continuing operations was **$4.5 million**, but a **$7.0 million** gain from subsidiary sale resulted in a total net income of **$2.7 million** Six Months Ended June 30, (in thousands of U.S. Dollars) | Metric | 2024 | 2025 | | :--- | :--- | :--- | | Revenue | $0 | $0 | | Research and development | ($1,550) | ($1,876) | | General and administrative | ($3,146) | ($2,683) | | Net loss from continuing operations | ($4,731) | ($4,462) | | Net income (loss) from discontinued operations | ($2,646) | $983 | | Net income (loss) attributable to BeyondSpring Inc. | ($7,262) | $2,671 | | Basic and diluted EPS | ($0.19) | $0.07 | [Condensed Consolidated Statements of Cash Flows](index=12&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) For H1 2025, net cash used in operating activities was **$10.1 million**, offset by **$17.2 million** from investing activities, resulting in a net cash increase of **$7.1 million** Cash Flow Summary for Six Months Ended June 30, (in thousands of U.S. Dollars) | Cash Flow Activity | 2024 | 2025 | | :--- | :--- | :--- | | Net cash used in operating activities | ($12,254) | ($10,072) | | Net cash provided by investing activities | $0 | $17,154 | | Net cash provided by financing activities | $3,000 | $0 | | Net increase (decrease) in cash | ($9,354) | $7,080 | [Notes to Condensed Consolidated Financial Statements](index=13&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Key notes detail the divestiture of SEED Therapeutics as a discontinued operation, collaboration agreements, and the company's deferred tax asset valuation allowance - The company approved a plan to sell 90-100% of its interest in SEED Therapeutics. The first closing occurred in February 2025 for **$7.35 million**, resulting in a recognized gain of **$7.0 million**. The company's ownership in SEED decreased to **40.12%** but it retained control[62](index=62&type=chunk)[68](index=68&type=chunk)[70](index=70&type=chunk) - The collaboration with Hengrui for Plinabulin in Greater China involves an upfront fee of **$31.0 million** (RMB 200 million) and potential milestones. No revenue has been recognized from this agreement as of June 30, 2025, and the upfront fee is recorded as deferred revenue[71](index=71&type=chunk)[72](index=72&type=chunk)[74](index=74&type=chunk) - The collaboration with Eli Lilly via subsidiary SEED involves an upfront fee of **$10 million** and potential milestones up to **$780 million**. Revenue from this agreement is recognized over time and is reported within discontinued operations[76](index=76&type=chunk)[77](index=77&type=chunk)[81](index=81&type=chunk) - As of June 30, 2025, the company maintained a full valuation allowance against its net deferred tax assets, believing it is more likely than not that they will not be realized[87](index=87&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)](index=33&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Plinabulin development, SEED Therapeutics divestiture, and H1 2025 financial results, noting decreased G&A and increased R&D expenses - The company's lead asset, Plinabulin, is being developed as an anti-cancer agent, with a focus on non-small cell lung cancer (NSCLC) patients who have progressed on checkpoint inhibitors. The company plans to file a New Drug Application (NDA) with China's NMPA[122](index=122&type=chunk)[124](index=124&type=chunk) - The company entered into agreements to sell a portion of its SEED preferred shares for **$35.4 million** in three tranches. The first closing in February 2025 yielded **$7.35 million**. Future closings are expected by December 2025 and December 2026[134](index=134&type=chunk) - As of June 30, 2025, continuing operations held **$9.5 million** in cash and cash equivalents. Management anticipates that current financial resources will be sufficient to meet operational expenses for the next 12 months[130](index=130&type=chunk)[161](index=161&type=chunk) [Results of Operations](index=38&type=section&id=Results%20of%20Operations) For H1 2025, R&D expenses increased by **21%** to **$1.9 million**, while G&A expenses decreased by **15%** to **$2.7 million**, improving net loss from continuing operations Comparison of Operating Results for the Six Months Ended June 30, (in thousands of U.S. Dollars) | Item | 2024 | 2025 | Change % | | :--- | :--- | :--- | :--- | | Research and development | ($1,550) | ($1,876) | 21% | | General and administrative | ($3,146) | ($2,683) | -15% | | Loss from operations | ($4,696) | ($4,559) | -3% | | Net loss from continuing operations | ($4,731) | ($4,462) | -6% | - The **$0.3 million** increase in R&D expenses for H1 2025 was primarily due to higher professional service fees for regulatory and CMC activities and increased research on Plinabulin combination therapies[155](index=155&type=chunk) - The **$0.4 million** decrease in G&A expenses for H1 2025 was mainly due to lower salary expenses from reduced administrative headcount and lower investor relations and D&O insurance costs[157](index=157&type=chunk) [Liquidity and Capital Resources](index=41&type=section&id=Liquidity%20and%20Capital%20Resources) Liquidity improved in H1 2025, with cash from continuing operations reaching **$9.5 million** due to the SEED equity sale, and current resources are sufficient for the next 12 months - The company financed operations through a combination of equity offerings, loans, sale of subsidiary interests, and collaboration arrangements. In February 2025, it received **$7.4 million** from the first closing of the SEED sale[160](index=160&type=chunk) - Net cash used in operating activities decreased to **$10.1 million** in H1 2025 from **$12.3 million** in H1 2024[160](index=160&type=chunk)[162](index=162&type=chunk) - Management is evaluating various financing alternatives for medium to long-term funding, including equity/debt financing, licensing, partnerships, or other strategic transactions[161](index=161&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=45&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, BeyondSpring Inc. is exempt from providing quantitative and qualitative disclosures about market risk - The company is exempt from providing quantitative and qualitative disclosures about market risk because it qualifies as a smaller reporting company under Exchange Act Rule 12b-2[181](index=181&type=chunk) [Controls and Procedures](index=45&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of June 30, 2025, with no material changes to internal control over financial reporting - Based on an evaluation as of June 30, 2025, the Principal Executive and Financial Officer concluded that the company's disclosure controls and procedures were effective[182](index=182&type=chunk) - No changes in internal control over financial reporting occurred during the quarter that materially affected, or are reasonably likely to materially affect, these controls[184](index=184&type=chunk) [PART II. OTHER INFORMATION](index=46&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Legal Proceedings](index=46&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently a party to any legal proceedings that would materially adversely affect its business or financial condition - As of the filing date, the company is not involved in any material legal proceedings[186](index=186&type=chunk) [Risk Factors](index=46&type=section&id=Item%201A.%20Risk%20Factors) There are no material changes to the risk factors previously disclosed in the company's 2024 Annual Report on Form 10-K - The company states there are no material changes from the risk factors disclosed in its 2024 Annual Report on Form 10-K[187](index=187&type=chunk) [Exhibits](index=47&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, primarily including officer certifications and Inline XBRL data files - Exhibits filed include CEO/CFO certifications pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act[192](index=192&type=chunk)

[Corporate and Clinical Highlights](index=1&type=section&id=Corporate%20and%20Clinical%20Highlights) BeyondSpring reported significant clinical progress for Plinabulin in NSCLC and SEED Therapeutics achieved FDA IND clearance for ST-01156 [CEO's Statement](index=1&type=section&id=CEO%27s%20Statement) CEO Dr. Lan Huang emphasized Plinabulin's immune-modulating potential and SEED Therapeutics' ST-01156 FDA IND clearance - Plinabulin is positioned as a first-in-class agent that harnesses the body's immune system by maturing dendritic cells, bridging innate and adaptive immunity[3](index=3&type=chunk) - The combination of plinabulin and docetaxel has shown durable survival benefits and reduced chemotherapy-induced neutropenia in a global Phase 3 trial[3](index=3&type=chunk) - SEED Therapeutics' oral RBM39 molecular glue degrader, ST-01156, received FDA clearance to enter clinical trials for aggressive cancers like Ewing Sarcoma and KRAS-driven tumors[3](index=3&type=chunk) [Key Milestones](index=1&type=section&id=Key%20Milestones) Key milestones include Plinabulin's ASCO 2025 presentation, 'Med' publication, SEED Therapeutics' ST-01156 FDA IND clearance, and new leadership - ASCO 2025 presentation highlighted Plinabulin's ability to drive immune re-sensitization in NSCLC patients who have progressed on PD-1/L1 therapies[5](index=5&type=chunk) - A publication in 'Med' (Cell Press) detailed Plinabulin's rapid activation of dendritic cells in patients across eight cancer types who had failed prior immunotherapy[5](index=5&type=chunk) - SEED Therapeutics' lead asset, RBM39 degrader ST-01156, received FDA IND clearance and is advancing toward Phase 1 trials[5](index=5&type=chunk) - Dr. Bill Desmarais was appointed as the new CFO and CBO of SEED Therapeutics to accelerate development[5](index=5&type=chunk) [Plinabulin Clinical Updates](index=1&type=section&id=Plinabulin%20Clinical%20Updates) Plinabulin's Phase 2 NSCLC study showed encouraging efficacy, and a publication with MD Anderson confirmed its dendritic cell maturation mechanism Plinabulin Phase 2 NSCLC Study Efficacy Data (ASCO 2025) | Metric | Result | | :--- | :--- | | Median Progression-Free Survival (PFS) | 6.8 months | | Confirmed Objective Response Rate (ORR) | 18.2% | | Duration of Response (DOR) | 7.2 months | | Disease Control Rate (DCR) | 77% | | Overall Survival (OS) at 15 months | 78% | - A study with MD Anderson showed Plinabulin, combined with radiation and a checkpoint inhibitor, rapidly induces dendritic cell maturation in patients who failed prior immunotherapy[6](index=6&type=chunk) - In the MD Anderson study across eight cancer types, the combination therapy achieved an Objective Response Rate (ORR) of **23%** and a Disease Control Rate (DCR) of **54%**[6](index=6&type=chunk) [SEED Therapeutics Updates](index=1&type=section&id=SEED%20Therapeutics%20Updates) SEED Therapeutics achieved FDA IND clearance for ST-01156, showing complete tumor regression in preclinical models, and appointed new leadership - The FDA cleared the IND application for ST-01156, a brain-penetrant, novel orally administered molecular glue degrader targeting RBM39[6](index=6&type=chunk)[7](index=7&type=chunk) - Preclinical data presented at AACR 2025 showed ST-01156 demonstrated complete tumor regression in Ewing Sarcoma models[9](index=9&type=chunk) - Dr. Bill Desmarais, Ph.D., MBA, joined SEED Therapeutics as CFO and Chief Business Officer, bringing over two decades of biopharma leadership experience[9](index=9&type=chunk) [Financial Performance](index=2&type=section&id=Financial%20Performance) BeyondSpring reported a reduced Q2 2025 net loss from continuing operations, improved cash, and reclassified SEED Therapeutics as discontinued operations [Q2 2025 Financial Results Summary](index=2&type=section&id=Q2%202025%20Financial%20Results%20Summary) Q2 2025 saw increased R&D, reduced G&A, a lower net loss, and a strengthened cash position for continuing operations Q2 Financial Highlights (Continuing Operations) | Metric | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | R&D Expenses | $1.0 million | $0.8 million | | G&A Expenses | $0.9 million | $1.8 million | | Net Loss | $1.9 million | $2.7 million | Cash Position | Metric | June 30, 2025 | Dec 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $9.5 million | $2.9 million | [Year-to-Date 2025 Financial Results Summary](index=2&type=section&id=Year-to-Date%202025%20Financial%20Results%20Summary) Year-to-date 2025 showed a slightly improved net loss from continuing operations and a total net income including discontinued operations Six-Month Financial Highlights (Continuing Operations) | Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | R&D Expenses | $1.9 million | $1.6 million | | G&A Expenses | $2.7 million | $3.1 million | | Net Loss | $4.5 million | $4.7 million | - Net income from discontinued operations was **$1.0 million** for the first six months of 2025, compared to a net loss of **$2.6 million** for the same period in 2024[8](index=8&type=chunk) [Accounting for SEED Therapeutics](index=2&type=section&id=Accounting%20for%20SEED%20Therapeutics) BeyondSpring reclassified SEED Therapeutics' financial results as discontinued operations after agreements to reduce its ownership stake - SEED Therapeutics' financial results are now reported as discontinued operations under ASC 205-20[9](index=9&type=chunk) - BeyondSpring's ownership in SEED is set to be reduced from approximately **40%** to **14%** upon completion of future sale transactions[10](index=10&type=chunk) [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2025, BeyondSpring's balance sheet showed increased cash, stable assets and liabilities, and a widened shareholders' deficit Selected Balance Sheet Data (in thousands) | Balance Sheet Item | June 30, 2025 | Dec 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $9,544 | $2,922 | | Total assets | $31,043 | $34,315 | | Total liabilities | $48,588 | $48,600 | | Total shareholders' deficit | ($17,545) | ($14,285) | [Condensed Consolidated Statements of Comprehensive Income (Loss)](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Comprehensive%20Income%20%28Loss%29) Q2 2025 showed no revenue and a net loss from continuing operations, with year-to-date results including net income from discontinued operations Income Statement Summary (in thousands, except per share data) | Metric | Q2 2025 | Q2 2024 | Six Months 2025 | Six Months 2024 | | :--- | :--- | :--- | :--- | :--- | | Revenue | $0 | $0 | $0 | $0 | | Loss from operations | ($1,949) | ($2,641) | ($4,559) | ($4,696) | | Net loss from continuing ops | ($1,878) | ($2,651) | ($4,462) | ($4,731) | | Net income (loss) from discontinued ops | ($2,771) | ($1,438) | $983 | ($2,646) | | EPS (Continuing ops) | ($0.04) | ($0.07) | ($0.11) | ($0.12) | [Company Overview](index=3&type=section&id=Company%20Overview) BeyondSpring is a clinical-stage biopharmaceutical company developing first-in-class therapies, featuring Plinabulin and affiliate SEED Therapeutics [About BeyondSpring](index=3&type=section&id=About%20BeyondSpring) BeyondSpring is a clinical-stage biopharmaceutical company focused on developing Plinabulin, a late-stage anti-cancer agent for NSCLC - The company's lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in NSCLC[11](index=11&type=chunk) - Plinabulin's novel mechanism as a dendritic cell maturation agent offers a unique approach to resensitizing tumors resistant to checkpoint inhibitors[11](index=11&type=chunk) [About SEED Therapeutics](index=3&type=section&id=About%20SEED%20Therapeutics) SEED Therapeutics specializes in targeted protein degradation via its RITE3™ platform, developing a pipeline with strategic partners - SEED Therapeutics pioneers targeted protein degradation through its proprietary RITE3™ platform[12](index=12&type=chunk) - The company has strategic collaborations with major pharmaceutical companies Eli Lilly and Eisai[12](index=12&type=chunk) - SEED's lead RBM39 degrader program has received US FDA IND clearance[12](index=12&type=chunk) [Cautionary Note Regarding Forward-Looking Statements](index=3&type=section&id=Cautionary%20Note%20Regarding%20Forward-Looking%20Statements) This section warns that forward-looking statements are subject to significant risks and uncertainties, which could cause actual results to differ - The press release contains forward-looking statements that are not historical facts and are based on current knowledge, beliefs, and expectations[13](index=13&type=chunk) - Actual results could differ materially due to risks such as difficulties in raising capital, unexpected clinical trial results, regulatory delays, and market competition[13](index=13&type=chunk)

Core Insights - BeyondSpring Pharmaceuticals (BYSI) experienced a stock price increase of 3.19% on August 8, reaching $2.105 per share, with a total market capitalization of $84.8785 million [1] - As of June 30, 2024, the company reported total revenue of $1 million, reflecting a year-over-year growth of 14.29%, while the net profit attributable to shareholders was -$7.262 million, showing a 42.91% increase in losses compared to the previous year [1] - The company is focused on developing novel cancer therapies, particularly advanced tumor immunotherapy, and aims to transform cancer treatment through its unique academic and business capabilities [1] Financial Performance - Total revenue for the fiscal year ending June 30, 2024, is projected at $1 million, marking a 14.29% increase year-over-year [1] - The net profit attributable to shareholders is reported at -$7.262 million, which is a 42.91% increase in losses compared to the previous year [1] Company Overview - BeyondSpring Pharmaceuticals is a clinical-stage biopharmaceutical company established in 2013, headquartered in the United States [1] - The company specializes in the research and development of new cancer therapies, including treatments for non-small cell lung cancer and the prevention of neutropenia [1] - The main project, Plinabulin, is derived from natural compounds and has therapeutic potential for various cancers [1] - BeyondSpring employs a novel, highly scalable business model that integrates resources from the U.S. and China to efficiently and cost-effectively achieve drug approval and development [1]

Group 1 - The stock price of BeyondSpring Inc. (BYSI) increased by 5.07% on August 6, reaching $2.154 per share, with a total market capitalization of $86.8373 million [1] - As of June 30, 2024, BeyondSpring reported total revenue of $1.0 million, reflecting a year-over-year growth of 14.29%, while the net profit attributable to shareholders was -$7.262 million, showing a year-over-year increase of 42.91% [1] Group 2 - BeyondSpring is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, including advanced tumor immunotherapy [2] - The company was founded in 2013 and is headquartered in the United States, with a mission to transform cancer treatment through its academic and business capabilities [2] - The main project, Plinabulin, is derived from natural compounds and has therapeutic potential for various cancers, with a novel, scalable business model aimed at efficient and low-cost drug approval and development [2] - Target research areas include non-small cell lung cancer, prevention of neutropenia, and Plinabulin combined with PD-1 monoclonal antibodies [2]

Group 1 - The stock price of BeyondSpring Inc. (BYSI) increased by 5.8% on August 4, reaching $2.19 per share, with a total market capitalization of $88.29 million [1] - As of June 30, 2024, BeyondSpring reported total revenue of $1.00 million, representing a year-over-year growth of 14.29%, while the net profit attributable to the parent company was -$7.26 million, showing a year-over-year increase of 42.91% [1] - BeyondSpring is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, including advanced tumor immunotherapy [1] Group 2 - The company was founded in 2013 and is headquartered in the United States, with a mission to transform cancer treatment through its academic and business capabilities [1] - BeyondSpring's main project, Plinabulin, is derived from natural compounds and has therapeutic potential for various cancers due to its biochemical activities [1] - The company employs a novel, highly scalable business model that integrates resources from the U.S. and China to efficiently and cost-effectively achieve drug approval and development [1]

Core Insights - BeyondSpring Pharmaceuticals (BYSI) experienced a stock price increase of 3.38% on August 4, reaching $2.14 per share, with a total market capitalization of approximately $86.28 million [1] - As of June 30, 2024, the company reported total revenue of $1.00 million, reflecting a year-over-year growth of 14.29%, while the net loss attributable to shareholders was $7.26 million, which represents a 42.91% increase compared to the previous year [1] Company Overview - BeyondSpring Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, including advanced tumor immunotherapy [2] - The company was founded in 2013 and is headquartered in the United States, with a mission to transform cancer treatment through its academic and business capabilities [2] - The primary project, Plinabulin, is derived from natural compounds and has therapeutic potential for various cancers due to its biochemical activities [2] - BeyondSpring employs a novel, highly scalable business model that integrates resources from both the U.S. and China to efficiently and cost-effectively achieve drug approval and development [2] - Target research areas include non-small cell lung cancer, prevention of neutropenia, and Plinabulin combined with PD-1 monoclonal antibodies [2]

Core Insights - BeyondSpring Pharmaceuticals (BYSI) experienced a stock price increase of 2.22%, reaching $2.075 per share, with a total market capitalization of $83.6564 million as of August 1 [1] - For the fiscal year ending June 30, 2024, the company reported total revenue of $1 million, reflecting a year-over-year growth of 14.29%, while the net profit attributable to shareholders was -$7.262 million, showing a 42.91% increase in losses compared to the previous year [1] - The company is set to release its fiscal year 2024 annual report on May 5, with the actual disclosure date subject to company announcements [1] Company Overview - BeyondSpring Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, including advanced tumor immunotherapy [1] - Established in 2013 and headquartered in the United States, the company aims to leverage its academic and business expertise in cancer treatment to transform the current landscape of cancer therapy [1] - The primary project, Plinabulin, is derived from natural compounds and has therapeutic potential for various cancers due to its biochemical activities [1] Business Model and Research Focus - The company employs an innovative and highly scalable business model that integrates resources from both the U.S. and China to efficiently and cost-effectively achieve drug approval and development [1] - Key research areas include non-small cell lung cancer, prevention of neutropenia, and the combination of Plinabulin with PD-1 monoclonal antibodies [1]